Deciding on Success Criteria for Predictability of Pharmacokinetic Parameters from In Vitro Studies: An Analysis Based on In Vivo Observations
暂无分享,去创建一个
Khaled Abduljalil | Amin Rostami-Hodjegan | A. Rostami-Hodjegan | K. Abduljalil | T. Cain | H. Humphries | Theresa Cain | Helen Humphries
[1] M Zschiesche,et al. Oral bioavailability of digoxin is enhanced by talinolol: Evidence for involvement of intestinal P‐glycoprotein , 2000, Clinical pharmacology and therapeutics.
[2] U. Fuhr,et al. Assessment of Activity Levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 Genes by Population Pharmacokinetics of Dextromethorphan , 2010, Clinical pharmacology and therapeutics.
[3] J. Villeneuve,et al. Plasma binding and disposition of furosemide in the nephrotic syndrome and in uremia , 1978, Clinical pharmacology and therapeutics.
[4] D. Greenblatt,et al. Propranolol interactions with diazepam, lorazepam, and alprazolam , 1984 .
[5] J. Chien,et al. Optimization of Drug-Drug Interaction Study Design: Comparison of Minimal Physiologically Based Pharmacokinetic Models on Prediction of CYP3A Inhibition by Ketoconazole , 2013, Drug Metabolism and Disposition.
[6] U. Klotz,et al. Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction , 1998, Clinical pharmacology and therapeutics.
[7] R. Vestal,et al. Theophylline metabolism in healthy nonsmokers and in patients with insulin‐dependent diabetes mellitus , 1995, Clinical pharmacology and therapeutics.
[8] Koujirou Yamamoto,et al. Kidneys contribute to the extrahepatic clearance of propofol in humans, but not lungs and brain. , 2005, British journal of clinical pharmacology.
[9] D. Stanski,et al. Chronic alcohol intake does not change thiopental anesthetic requirement, pharmacokinetics, or pharmacodynamics. , 1990, Anesthesiology.
[10] L. Shaw,et al. Is the Volume of Distribution of Digoxin Reduced in Patients with Renal Dysfunction? Determining Digoxin Pharmacokinetics by Fluorescence Polarization Immunoassay , 1997, Pharmacotherapy.
[11] D. Crankshaw,et al. The Short Term Distribution of Thiopentone in the Dog , 1979, Anaesthesia and intensive care.
[12] E. Mikkelsen,et al. Distribution, elimination and effect of furosemide in normal subjects and in patients with heart failure , 1977, European Journal of Clinical Pharmacology.
[13] G. Drusano,et al. Effect of renal function on the bioavailability of ciprofloxacin , 1990, Antimicrobial Agents and Chemotherapy.
[14] D. Jonker,et al. Pharmacokinetics and pharmacodynamics of midazolam administered as a concentrated intranasal spray. A study in healthy volunteers. , 2002, British journal of clinical pharmacology.
[15] D. Greenblatt,et al. Lorazepam and oxazepam kinetics in women on low‐dose oral contraceptives , 1983, Clinical pharmacology and therapeutics.
[16] G. Tucker,et al. Prediction of in vivo drug clearance from in vitro data. I: Impact of inter-individual variability , 2006, Xenobiotica; the fate of foreign compounds in biological systems.
[17] S. Barriere,et al. Alteration in the pharmacokinetic disposition of ciprofloxacin by simultaneous administration of azlocillin , 1990, Antimicrobial Agents and Chemotherapy.
[18] P. Neuvonen,et al. The Effect of Intravenous and Oral Fluconazole on the Pharmacokinetics and Pharmacodynamics of Intravenous Alfentanil , 1998, Anesthesia and analgesia.
[19] D. Greenblatt,et al. Single‐ and multiple‐dose kinetics of intravenous digoxin , 1980, Clinical pharmacology and therapeutics.
[20] O. D. de Noord,et al. Effects of alpha-interferon on theophylline pharmacokinetics and metabolism. , 1989, British journal of clinical pharmacology.
[21] J. Miners,et al. The effect of ranitidine on the disposition of lignocaine. , 1985, British journal of clinical pharmacology.
[22] T. Bergan,et al. The pharmacokinetics of one single preoperative dose of metronidazole or tinidazole. , 1984, Scandinavian journal of gastroenterology. Supplement.
[23] J. Standefer,et al. Effect of norfloxacin on theophylline metabolism , 1989, Antimicrobial Agents and Chemotherapy.
[24] J. Lin,et al. Comparative effect of famotidine and cimetidine on the pharmacokinetics of theophylline in normal volunteers. , 1987, British journal of clinical pharmacology.
[25] J. Maddocks,et al. The plasma half-life of antipyrine in chromic uraemic and normal subjects. , 1975, British journal of clinical pharmacology.
[26] E. Wodey,et al. Absolute bioavailability of midazolam after subcutaneous administration to healthy volunteers. , 2002, British journal of clinical pharmacology.
[27] L. Benet,et al. Attenuation of furosemide's diuretic effect by indomethacin: Pharmacokinetic evaluation , 1979, Journal of Pharmacokinetics and Biopharmaceutics.
[28] D. Greenblatt,et al. Pharmacokinetics and Bioavailability of Intravenous, Intramuscular, and Oral Lorazepam in Humans , 1979 .
[29] R. Feldman,et al. The Effects of Activated Charcoal on Digoxin and Digitoxin Clearance , 1985, Drug intelligence & clinical pharmacy.
[30] I. Cascorbi,et al. Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms. , 2006, British journal of clinical pharmacology.
[31] Stephan Krähenbühl,et al. Sublingual administration of furosemide: new application of an old drug. , 2007, British journal of clinical pharmacology.
[32] E. Kharasch,et al. The Role of Cytochrome P450 3A4 in Alfentanil Clearance: Implications for Interindividual Variability in Disposition and Perioperative Drug Interactions , 1997, Anesthesiology.
[33] A. Lau,et al. Pharmacokinetics of intravenous metronidazole at different dosages in healthy subjects. , 1991, International journal of clinical pharmacology, therapy, and toxicology.
[34] F. Andreasen,et al. Thiopentone sensitivity in young and elderly women. , 1983, British journal of anaesthesia.
[35] J. Segal,et al. Decreased Systemic Clearance of Lorazepam in Humans With Spinal Cord Injury , 1991, Journal of clinical pharmacology.
[36] D R Stanski,et al. The Effect of Increasing Age on Thiopental Disposition and Anesthetic Requirement , 1985, Anesthesiology.
[37] M. Ghoneim,et al. Pharmacokinetics of thiopentone: effects of enflurane and nitrous oxide anaesthesia and surgery. , 1978, British journal of anaesthesia.
[38] J. Monasterio,et al. Plasma concentrations and bioavailability of propranolol by oral, rectal, and intravenous administration in man. , 1986, Biopharmaceutics & drug disposition.
[39] D. Morgan,et al. Influence of chronic dosing on theophylline clearance. , 1985, British journal of clinical pharmacology.
[40] F. Andreasen,et al. Influence of age and sex on the pharmacokinetics of thiopentone. , 1981, British journal of anaesthesia.
[41] Werner Siegmund,et al. The effects of the human MDR1 genotype on the expression of duodenal P‐glycoprotein and disposition of the probe drug talinolol , 2002, Clinical pharmacology and therapeutics.
[42] G. Shorten,et al. Elimination of alfentanil delivered by infusion is not altered by the chronic administration of atorvastatin , 2003, European journal of anaesthesiology.
[43] H. Glaeser,et al. P‐glycoprotein‐mediated intestinal and biliary digoxin transport in humans , 2003, Clinical pharmacology and therapeutics.
[44] T. Bergan,et al. Pharmacokinetics and bioavailability of metronidazole after tablets, suppositories and intravenous administration. , 1984, Scandinavian journal of gastroenterology. Supplement.
[45] D. Bevan,et al. Concentration–Effect Relationship of Cisatracurium at Three Different Dose Levels in the Anesthetized Patient , 2001, Anesthesiology.
[46] A. Hiller,et al. A potentially hazardous interaction between erythromycin and midazolam , 1993 .
[47] A. Vandesteene,et al. Propofol infusion for induction and maintenance of anaesthesia in patients with end-stage renal disease. , 1998, British journal of anaesthesia.
[48] M. Pinaud,et al. Pharmacodynamic Dose-Response and Safety Study of Cisatracurium (51W89) in Adult Surgical Patients During N2 O-O2-Opioid Anesthesia , 1996, Anesthesia and analgesia.
[49] T. Bouillon,et al. Non–steady State Analysis of the Pharmacokinetic Interaction between Propofol and Remifentanil , 2002, Anesthesiology.
[50] R. Orlando,et al. Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: Effects of liver function , 2004, Clinical pharmacology and therapeutics.
[51] J. Lettieri,et al. Pharmacokinetics of high-dose intravenous ciprofloxacin in young and elderly and in male and female subjects , 1995, Antimicrobial agents and chemotherapy.
[52] U Klotz,et al. Midazolam kinetics , 1981, Clinical pharmacology and therapeutics.
[53] D. Greenblatt,et al. Acetaminophen pharmacokinetics in women receiving conjugated estrogen , 2004, European Journal of Clinical Pharmacology.
[54] A. Richens,et al. Pharmacokinetics of diazepam in epileptic patients and normal volunteers following intravenous administration. , 1981, British journal of clinical pharmacology.
[55] Critique of the Two-Fold Measure of Prediction Success for Ratios: Application for the Assessment of Drug-Drug Interactions , 2011, Drug Metabolism and Disposition.
[56] D. Greenblatt,et al. Lack of Effect of Influenza Vaccine on the Pharmacokinetics of Antipyrine, Alprazolam, Paracetamol (Acetaminophen) and Lorazepam , 1989, Clinical pharmacokinetics.
[57] D. Greenblatt,et al. Fentanyl Clearance and Volume of Distribution Are Increased in Patients With Major Burns , 2007, Journal of clinical pharmacology.
[58] Kairui Feng,et al. The Simcyp population-based ADME simulator. , 2009, Expert opinion on drug metabolism & toxicology.
[59] N. Grégoire,et al. Safety and Pharmacokinetics of Paracetamol Following Intravenous Administration of 5 g During the First 24 h with a 2‐g Starting Dose , 2007, Clinical pharmacology and therapeutics.
[60] K Rowland-Yeo,et al. Prediction of in vivo drug clearance from in vitro data. II: Potential inter-ethnic differences , 2006, Xenobiotica; the fate of foreign compounds in biological systems.
[61] D. Greenblatt,et al. Simplified approaches to the determination of antipyrine pharmacokinetic parameters. , 1988, British journal of clinical pharmacology.
[62] D. Bateman,et al. Effects of time of dosing and age on intravenous aminophylline pharmacokinetics. , 1987, British journal of clinical pharmacology.
[63] A. Howell,et al. Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy , 2010, Breast Cancer Research and Treatment.
[64] M. Nunlee,et al. Failure of Ceftibuten to Alter Single Dose Theophylline Clearance , 1990, Journal of clinical pharmacology.
[65] F. Kamali,et al. The influence of steady-state ciprofloxacin on the pharmacokinetics and pharmacodynamics of a single dose of diazepam in healthy volunteers , 2004, European Journal of Clinical Pharmacology.
[66] P. Chouinard,et al. Cisatracurium-Induced Neuromuscular Blockade Is Affected by Chronic Phenytoin or Carbamazepine Treatment in Neurosurgical Patients , 2005, Anesthesia and analgesia.
[67] T. Walle,et al. Early kinetics of intravenous propranolol. , 1982, British journal of clinical pharmacology.
[68] P. Neuvonen,et al. Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam , 2006 .
[69] R. Branch,et al. A study of factors influencing drug disposition in chronic liver disease, using the model drug (+)-propranolol. , 1976, British Journal of Clinical Pharmacology.
[70] P. Hinderling,et al. Pharmacokinetics of Digoxin and Main Metabolites/Derivatives in Healthy Humans , 1991, Therapeutic drug monitoring.
[71] R. Gugler,et al. Interaction between metronidazole and drugs eliminated by oxidative metabolism , 1985, Clinical pharmacology and therapeutics.
[72] V. Steinijans,et al. The influence of caffeine on the steady‐state pharmacokinetics of theophylline , 1991, Clinical pharmacology and therapeutics.
[73] D. Greenblatt,et al. Pomegranate Juice Does Not Impair Clearance of Oral or Intravenous Midazolam, a Probe for Cytochrome P450‐3A Activity: Comparison With Grapefruit Juice , 2007, Journal of clinical pharmacology.
[74] U. Fuhr,et al. Plasma 4β‐Hydroxycholesterol: An Endogenous CYP3A Metric? , 2009, Clinical pharmacology and therapeutics.
[75] M. Chow,et al. The pharmacokinetic and pharmacodynamic interaction between propafenone and lidocaine , 1993, Clinical pharmacology and therapeutics.
[76] U. Spengler,et al. The lignocaine metabolite (MEGX) liver function test and P-450 induction in humans. , 1998, British journal of clinical pharmacology.
[77] P. G. Burch,et al. Decreased protein binding and thiopental kinetics , 1982, Clinical pharmacology and therapeutics.
[78] D. Greenblatt,et al. Effect of Age, Gender, and Obesity on Midazolam Kinetics , 1984, Anesthesiology.
[79] L. Paalzow,et al. Pharmacokinetics of furosemide in man after intravenous and oral administration. Application of moment analysis , 2004, European Journal of Clinical Pharmacology.
[80] J. Barré,et al. Comparative Pharmacokinetics of Intravenous Propranolol in Obese and Normal Volunteers , 1987, Journal of clinical pharmacology.
[81] K Walton,et al. Human variability in polymorphic CYP2D6 metabolism: is the kinetic default uncertainty factor adequate? , 2002, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[82] M. Rawlins,et al. Pharmacokinetics of paracetamol (acetaminophen) after intravenous and oral administration , 1977, European Journal of Clinical Pharmacology.
[83] A. Forrey,et al. Pharmacokinetics of orally administered furosemide. , 1974, Clinical pharmacology and therapeutics.
[84] D. Morgan,et al. Extended blood collection period required to define distribution and elimination kinetics of propofol. , 1988, British journal of clinical pharmacology.
[85] G. Drusano,et al. Sex differences in CYP3A activity using intravenous and oral midazolam , 2006, Clinical pharmacology and therapeutics.
[86] C. Regårdh,et al. Plasma Concentrations and Beta‐Blocking Effects in Normal Volunteers After Intravenous Doses of Metoprolol and Propranolol , 1980, Journal of cardiovascular pharmacology.
[87] K H Antonin,et al. Pharmacokinetics and plasma binding of diazepam in man, dog, rabbit, guinea pig and rat. , 1976, The Journal of pharmacology and experimental therapeutics.
[88] P. Neuvonen,et al. The Effect of Erythromycin and Fluvoxamine on the Pharmacokinetics of Intravenous Lidocaine , 2005, Anesthesia and analgesia.
[89] B. Beermann,et al. Elimination of furosemide in healthy subjects and in those with renal failure , 1977, Clinical pharmacology and therapeutics.
[90] D. Greenblatt,et al. Differential effect of cigarette smoking on antipyrine oxidation versus acetaminophen conjugation. , 1990, Pharmacology.
[91] Jerome J. Schentag,et al. Effects of the Concomitant Administration of Tamsulosin (0.8 mg/Day) on the Pharmacokinetic and Safety Profile of Theophylline (5 mg/kg): A Placebo-Controlled Evaluation , 2002, The Journal of international medical research.
[92] J. Paull,et al. Pharmacokinetics and plasma binding of thiopental. I: Studies in surgical patients. , 1981, Anesthesiology.
[93] Kairui Feng,et al. The Simcyp® Population-based ADME Simulator , 2009 .
[94] C. Nord,et al. Systemic concentrations of metronidazole and its main metabolites after intravenous oral and vaginal administration. , 1987, Gynecologic and obstetric investigation.
[95] Pharmacodynamics and Pharmacokinetics of Cisatracurium in Geriatric Surgical Patients , 1996, Anesthesiology.
[96] N. T. Smith,et al. Aging and alfentanil disposition in healthy volunteers and surgical patients , 1989, Canadian journal of anaesthesia = Journal canadien d'anesthesie.
[97] F. Andreasen,et al. Comparison of the anaesthetic and haemodynamic effects of chlormethiazole and thiopentone. , 1983, British journal of anaesthesia.
[98] J. Gugenheim,et al. Hepatic Disposition of Alfentanil and Sufentanil in Patients Undergoing Orthotopic Liver Transplantation , 1997, Anesthesia and analgesia.
[99] D. Greenblatt,et al. Desmethyldiazepam Pharmacokinetics: Studies Following Intravenous and Oral Desmethyldiazepam, Oral Clorazepate, and Intravenous Diazepam , 1988, Journal of clinical pharmacology.
[100] L. Benet,et al. Absorption and disposition of furosemide in healthy volunteers, measured with a metabolite-specific assay. , 1980, Drug metabolism and disposition: the biological fate of chemicals.
[101] W. Jusko,et al. Pharmacokinetics of digoxin in normal subjects after intravenous bolus and infusion doses , 1975, Journal of Pharmacokinetics and Biopharmaceutics.
[102] H. Lode,et al. Pharmacokinetics of ciprofloxacin after oral and parenteral administration , 1985, Antimicrobial Agents and Chemotherapy.
[103] E. Kharasch,et al. Intraindividual Variability in Male Hepatic CYP3A4 Activity Assessed by Alfentanil and Midazolam Clearance , 1999, Journal of clinical pharmacology.
[104] W. Evans,et al. Hepatic drug clearance in patients with mild cystic fibrosis , 1996, Clinical pharmacology and therapeutics.
[105] D. Greenblatt,et al. Pharmacokinetics and bioavailability of digoxin capsules, solution and tablets after single and multiple doses. , 1978, The American journal of cardiology.
[106] G. Drusano,et al. Multiple-dose pharmacokinetics of ciprofloxacin administered intravenously to normal volunteers , 1985, Antimicrobial Agents and Chemotherapy.
[107] R. Oertel,et al. Disposition and bioavailability of the β1‐adrenoceptor antagonist talinolol in man , 1995, Biopharmaceutics & drug disposition.
[108] F Kesisoglou,et al. Prediction of Phase I single-dose pharmacokinetics using recombinant cytochromes P450 and physiologically based modelling , 2009, Xenobiotica; the fate of foreign compounds in biological systems.
[109] S. Wrighton,et al. The effects of an oral contraceptive containing ethinyloestradiol and norgestrel on CYP3A activity. , 2002, British journal of clinical pharmacology.
[110] W. Haefeli,et al. Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers , 2004, Clinical pharmacology and therapeutics.
[111] J. Clements,et al. A comparison of the pharmacokinetics of propranolol in obese and normal volunteers. , 1986, British journal of clinical pharmacology.
[112] D. Whittington,et al. Mechanism of Ritonavir Changes in Methadone Pharmacokinetics and Pharmacodynamics: II. Ritonavir Effects on CYP3A and P‐Glycoprotein Activities , 2008, Clinical pharmacology and therapeutics.
[113] C. Eap,et al. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment , 2005, Clinical pharmacology and therapeutics.
[114] D. Greenblatt,et al. Propofol Clearance and Volume of Distribution Are Increased in Patients With Major Burns , 2009, Journal of clinical pharmacology.
[115] E. Ganse,et al. Influence of lansoprazole treatment on diazepam plasma concentrations , 1992, Clinical pharmacology and therapeutics.
[116] P. de Micco,et al. Pharmacokinetics and tissue penetration of a single 1,000-milligram, intravenous dose of metronidazole for antibiotic prophylaxis of colorectal surgery , 1991, Antimicrobial Agents and Chemotherapy.
[117] D. Greenblatt,et al. Kinetic and dynamic study of intravenous lorazepam: comparison with intravenous diazepam. , 1989, The Journal of pharmacology and experimental therapeutics.
[118] T. Koizumi,et al. A study on furosemide disposition in man. , 1987, Journal of pharmacobio-dynamics.
[119] J S Harmatz,et al. Diazepam disposition determinants , 1980, Clinical pharmacology and therapeutics.
[120] M. Farinotti,et al. Thiopental Pharmacokinetics in Patients with Cirrhosis , 1983, Anesthesiology.
[121] D. Perrier,et al. Thiopental Disposition in Lean and Obese Patients Undergoing Surgery , 1982, Anesthesiology.
[122] P. Finley,et al. Lidocaine elimination: Effects of metoprolol and of propranolol , 1983, Clinical pharmacology and therapeutics.
[123] D. Greenblatt,et al. Diazepam kinetics in relation to age and sex. , 1981, Pharmacology.
[124] Amin Rostami-Hodjegan,et al. Sources of interindividual variability in IVIVE of clearance: an investigation into the prediction of benzodiazepine clearance using a mechanistic population-based pharmacokinetic model , 2011, Xenobiotica; the fate of foreign compounds in biological systems.
[125] G. Drusano,et al. Dose ranging study and constant infusion evaluation of ciprofloxacin , 1986, Antimicrobial Agents and Chemotherapy.
[126] C. Doré,et al. The Pharmacokinetics of Alfentanil After Normothermic and Hypothermic Cardiopulmonary Bypass , 1995, Anesthesia and analgesia.
[127] P. Munt,et al. Dose-dependency of theophylline clearance and protein binding. , 1981, Thorax.
[128] S. Loft,et al. Influence of dose and route of administration on disposition of metronidazole and its major metabolites , 2004, European Journal of Clinical Pharmacology.
[129] Li-qin Wang,et al. Population pharmacokinetics of propofol in Chinese patients. , 2003, Acta pharmacologica Sinica.
[130] A. Forrey,et al. Pharmacokinetics of furosemide in normal subjects and functionally anephric patients , 1974, Clinical pharmacology and therapeutics.
[131] P. Carrupt,et al. Pharmacokinetics of β-adrenoceptor blockers in obese and normal volunteers , 1997 .
[132] S. Gotzkowsky,et al. Poor correlation between 6beta-hydroxycortisol:cortisol molar ratios and midazolam clearance as measure of hepatic CYP3A activity. , 2006, British journal of clinical pharmacology.
[133] Vijay K. Gombar,et al. Quantitative Structure − Activity Relationship Models of Clinical Pharmacokinetics : Clearance and Volume of Distribution , 2013 .
[134] Joo-Youn Cho,et al. Effect of the UGT2B15 Genotype on the Pharmacokinetics, Pharmacodynamics, and Drug Interactions of Intravenous Lorazepam in Healthy Volunteers , 2005, Clinical pharmacology and therapeutics.
[135] P. Neuvonen,et al. Pharmacokinetics of Intravenous Paracetamol in Elderly Patients , 2011, Clinical pharmacokinetics.
[136] D. Greenblatt,et al. Interaction of propoxyphene with diazepam, alprazolam and lorazepam. , 1985, British journal of clinical pharmacology.
[138] O. Blin,et al. The quinolone, flumequine, has no effect on theophylline pharmacokinetics , 2004, European Journal of Clinical Pharmacology.
[139] L. Prescott,et al. Furosemide disposition in patients on CAPD , 2004, European Journal of Clinical Pharmacology.
[140] D. Guay,et al. Steady-state pharmacokinetics of intravenous and oral ciprofloxacin in elderly patients , 1989, Antimicrobial Agents and Chemotherapy.
[141] H. E. Hansen,et al. Pharmacokinetics of furosemide in anephric patients and in normal subjects , 1978, European Journal of Clinical Pharmacology.
[142] J. Hunter,et al. Pharmacokinetics of 1R-cis 1'R-cis atracurium besylate (51W89) and plasma laudanosine concentrations in health and chronic renal failure. , 1995, British journal of anaesthesia.
[143] P. Neuvonen,et al. Effect of erythromycin and itraconazole on the pharmacokinetics of intravenous lignocaine , 1998, European Journal of Clinical Pharmacology.
[144] D. Flockhart,et al. Theophylline pharmacokinetics are not altered by lansoprazole in CYP2C19 poor metabolizers , 1999, Clinical pharmacology and therapeutics.
[145] R. Branch,et al. Determinants of response to frusemide in normal subjects. , 1977, British journal of clinical pharmacology.
[146] A. Masica,et al. In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam , 2004, Clinical pharmacology and therapeutics.
[147] D. Morgan,et al. Pharmacokinetics of propofol when given by intravenous infusion. , 1990, British journal of clinical pharmacology.
[148] B. Goh,et al. Ketoconazole Renders Poor CYP3A Phenotype Status With Midazolam as Probe Drug , 2006, Therapeutic drug monitoring.
[149] J. Witte,et al. CYP3A activity in African American and European American men: Population differences and functional effect of the CYP3A4*1B 5′‐promoter region polymorphism , 2000, Clinical pharmacology and therapeutics.
[150] D. Greenblatt,et al. Kinetics of diazepam, midazolam, and lorazepam in cigarette smokers. , 1985, Chest.
[151] H. Eichler,et al. Target Site Concentrations of Ciprofloxacin after Single Intravenous and Oral Doses , 2002, Antimicrobial Agents and Chemotherapy.
[152] W. Evans,et al. Lorazepam pharmacodynamics and pharmacokinetics in children. , 1989, The Journal of pediatrics.
[153] D. Greenblatt,et al. Pharmacokinetic Comparison of Sublingual Lorazepam with Intravenous, Intramuscular, and Oral Lorazepam , 1982 .
[154] M. Relling,et al. Age‐related differences in hepatic drug clearance in children: Studies with lorazepam and antipyrine , 1991, Clinical pharmacology and therapeutics.
[155] G. Drusano,et al. Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function , 1987, Antimicrobial Agents and Chemotherapy.
[156] D. Greenblatt,et al. Dose-independent pharmacokinetics of digoxin in humans. , 1978, American heart journal.
[157] M. Spino,et al. Cystic fibrosis: enhanced theophylline metabolism may be linked to the disease , 1988, Clinical pharmacology and therapeutics.
[158] J. Natarajan,et al. Absence of a Pharmacokinetic Interaction Between Intravenous Theophylline and Orally Administered Levofloxacin , 1997, Journal of clinical pharmacology.
[159] R. Mumm,et al. Influence of hepatic cirrhosis and end-stage renal disease on pharmacokinetics and pharmacodynamics of furosemide , 2004, European Journal of Clinical Pharmacology.
[160] S. Krähenbühl,et al. Interaction between grapefruit juice and midazolam in humans , 1995, Clinical pharmacology and therapeutics.
[161] M. Dudley,et al. Effect of dose on serum pharmacokinetics of intravenous ciprofloxacin with identification and characterization of extravascular compartments using noncompartmental and compartmental pharmacokinetic models , 1987, Antimicrobial Agents and Chemotherapy.
[162] D. Greenblatt,et al. Interaction of Diazepam With Famotidine and Cimetidine, Two H2‐Receptor Antagonists , 1986, Journal of clinical pharmacology.
[163] G. Novelli,et al. Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians. , 2007, Pharmacogenomics.
[164] P. Fenster,et al. Effect of quinine on digoxin kinetics , 1980, Clinical pharmacology and therapeutics.
[165] D. Greenblatt,et al. Effect of antipyrine coadministration on the kinetics of acetaminophen and lidocaine , 2004, European Journal of Clinical Pharmacology.
[166] U. Klotz,et al. Physiologie and temporal variation in hepatic elimination of midazolam , 1982, Clinical pharmacology and therapeutics.
[167] E. Olofsen,et al. Mixed-effects Modeling of the Influence of Alfentanil on Propofol Pharmacokinetics , 2004, Anesthesiology.
[168] Yuan Chen,et al. Application of IVIVE and PBPK modeling in prospective prediction of clinical pharmacokinetics: strategy and approach during the drug discovery phase with four case studies , 2012, Biopharmaceutics & drug disposition.
[169] P. Fiset,et al. Pharmacokinetics and Pharmacodynamics of Cisatracurium After a Short Infusion in Patients Under Propofol Anesthesia , 1998, Anesthesia and analgesia.
[170] U. Klotz,et al. The effects of age and liver disease on the disposition and elimination of diazepam in adult man. , 1975, The Journal of clinical investigation.
[171] R. Wise,et al. Pharmacokinetics of intravenously administered ciprofloxacin , 1984, Antimicrobial Agents and Chemotherapy.
[172] J. Mucklow,et al. The rise and fall of serum theophylline concentration: a comparison of sustained-release formulations in volunteers with rapid theophylline clearance. , 1985, British journal of clinical pharmacology.
[173] C. Swift,et al. Serum cystatin C is not a better marker of creatinine or digoxin clearance than serum creatinine. , 2002, British journal of clinical pharmacology.
[174] K. Thummel,et al. CYP3A activity in European American and Japanese men using midazolam as an in vivo probe , 2001, Clinical pharmacology and therapeutics.
[175] T. Vree,et al. The effect of multiple-dose oral lomefloxacin on theophylline metabolism in man. , 1990, Chest.
[176] C. Hull,et al. Pharmacokinetics and Pharmacodynamics of Cisatracurium in Young and Elderly Adult Patients , 1996, Anesthesiology.
[177] A. Dahan,et al. Mixed-Effects Modeling of the Influence of Midazolam on Propofol Pharmacokinetics , 2009, Anesthesia and analgesia.
[178] Malcolm Rowland,et al. Use of microdosing to predict pharmacokinetics at the therapeutic dose: Experience with 5 drugs , 2006, Clinical pharmacology and therapeutics.
[179] H. Halkin,et al. Interindividual variability in sensitivity to warfarin‐Nature or nurture? , 2001, Clinical pharmacology and therapeutics.
[180] C. George,et al. The effect of ageing on the hepatic clearance of propranolol. , 1979, British journal of clinical pharmacology.
[181] B L Ehrenberg,et al. Pharmacokinetic and electroencephalographic study of intravenous diazepam, midazolam, and placebo , 1989, Clinical pharmacology and therapy.
[182] D. Morgan,et al. Pharmacokinetics and plasma binding of thiopental. II: Studies at cesarean section. , 1981, Anesthesiology.
[183] S M Archer,et al. Bioavailability and Pharmacokinetics of Lorazepam after Intranasal, Intravenous, and Intramuscular Administration , 2001, Journal of clinical pharmacology.
[184] M. J. Eadie,et al. The pharmacokinetics of midazolam in man , 2004, European Journal of Clinical Pharmacology.
[185] G. De Nucci,et al. Plasma hydroxy-metronidazole/metronidazole ratio in patients with liver disease and in healthy volunteers. , 1995, British journal of clinical pharmacology.
[186] P Heizmann,et al. Pharmacokinetics and bioavailability of midazolam in man. , 1983, British journal of clinical pharmacology.
[187] J. W. A. S. Sander,et al. A comparative pharmacokinetic study of intravenous and intramuscular midazolam in patients with epilepsy , 1991, Epilepsy Research.
[188] W. Kraft,et al. Effect of Aprepitant on the Pharmacokinetics of Intravenous Midazolam , 2007, Journal of clinical pharmacology.
[189] E. Kharasch,et al. A pilot evaluation of alfentanil‐induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans , 2001, Clinical pharmacology and therapeutics.
[190] D. Greenblatt,et al. Pharmacokinetics and pharmacodynamics of intravenous digoxin and digitoxin , 1981, Klinische Wochenschrift.
[191] R. Orlando,et al. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis , 2006, Clinical pharmacology and therapeutics.
[192] G. Thompson,et al. Assessment of doxylamine influence on mixed function oxidase activity upon multiple dose oral administration to normal volunteers. , 1996, Journal of pharmaceutical sciences.
[193] N. Chalasani,et al. Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: Effects of transjugular intrahepatic portosystemic shunts , 2001, Hepatology.
[194] Juliana Barr,et al. Remifentanil Versus Alfentanil: Comparative Pharmacokinetics and Pharmacodynamics in Healthy Adult Male Volunteers , 1996, Anesthesiology.
[195] Michael Zschiesche,et al. Induction of P‐glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: A new type of drug/drug interaction , 2000, Clinical pharmacology and therapeutics.
[196] J. Lettieri,et al. Ciprofloxacin pharmacokinetics in burn patients , 1996, Antimicrobial agents and chemotherapy.
[197] G. Granneman,et al. The Effects of Lansoprazole on the Disposition of Antipyrine and Indocyanine Green in Normal Human Subjects. , 1995, American journal of therapeutics.
[198] Michael Zschiesche,et al. Carbamazepine regulates intestinal P‐glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans , 2004, Clinical pharmacology and therapeutics.
[199] F. Sörgel,et al. Effect of probenecid on the distribution and elimination of ciprofloxacin in humans , 1995, Clinical pharmacology and therapeutics.
[200] P. G. Burch,et al. Pharmacokinetics of Methohexital and Thiopental in Surgical Patients , 1983, Anesthesiology.
[201] E. Hellriegel,et al. Interaction Profile of Armodafinil with Medications Metabolized by Cytochrome P450 Enzymes 1A2, 3A4 and 2C19 in Healthy Subjects , 2008, Clinical pharmacokinetics.
[202] R. Mäntylä,et al. Comparative pharmacokinetics of metronidazole and tinidazole as influenced by administration route , 1983, Antimicrobial Agents and Chemotherapy.
[203] T. Bergan,et al. Transintestinal elimination of ciprofloxacin. , 1990, Chemotherapy.
[204] R. Orlando,et al. Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function. , 2003, British journal of clinical pharmacology.
[205] J. Dorne,et al. Polymorphic CYP2C19 and N-acetylation: human variability in kinetics and pathway-related uncertainty factors. , 2003, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[206] D. Shen,et al. Oral first‐pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A‐mediated metabolism , 1996, Clinical pharmacology and therapeutics.
[207] T. Andersson,et al. No Influence of Single Intravenous Doses of Omeprazole on Theophylline Elimination Kinetics , 1992, Journal of clinical pharmacology.
[208] P. Neuvonen,et al. Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half‐life , 2006, Clinical pharmacology and therapeutics.
[209] G. Wilkinson,et al. Disposition of diazepam in young and elderly subjects after acute and chronic dosing. , 1996, British journal of clinical pharmacology.
[210] G. Tucker,et al. Clinical implications of genetic polymorphism in drug metabolism. , 1994, The Journal of pharmacy and pharmacology.
[211] F. Andreasen,et al. Pharmacokinetics of thiopentone in a group of young women and a group of young men. , 1980, British journal of anaesthesia.
[212] W. Kirch,et al. Induction of Intestinal P‐glycoprotein by St John's Wort Reduces the Oral Bioavailability of Talinolol , 2007, Clinical pharmacology and therapeutics.
[213] R. Cutler,et al. Effects of probenecid on furosemide kinetics and natriuresis in man , 1977, Clinical pharmacology and therapeutics.
[214] U. Klotz,et al. Lack of pharmacokinetic interaction of pantoprazole with diazepam in man. , 1996, British journal of clinical pharmacology.
[215] S. Loft,et al. Therapeutic doses of codeine have no effect on acetaminophen clearance or metabolism , 2004, European Journal of Clinical Pharmacology.
[216] E. Kharasch,et al. Simultaneous Assessment of Drug Interactions with Low- and High-Extraction Opioids: Application to Parecoxib Effects on the Pharmacokinetics and Pharmacodynamics of Fentanyl and Alfentanil , 2003, Anesthesiology.
[217] D. Greenblatt,et al. Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. , 1983, The Journal of pharmacology and experimental therapeutics.
[218] P. Lundborg,et al. Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole , 1990, Clinical pharmacology and therapeutics.
[219] H. Seyberth,et al. Metamizole-furosemide interaction study in healthy volunteers , 2004, European Journal of Clinical Pharmacology.
[220] C. Roberts,et al. Influence of probenecid and spironolactone on furosemide kinetics and dynamics in man , 1977, Clinical pharmacology and therapeutics.
[221] D. Greenblatt,et al. Automated gas chromatography for studies of midazolam pharmacokinetics. , 1981, Anesthesiology.
[222] P. Jakobsen,et al. Pharmacokinetics and bioavailability of intravenous and intramuscular lorazepam with an adjunct test of the inattention effect in humans. , 2009, Acta pharmacologica et toxicologica.
[223] D. Greenblatt,et al. Metronidazole Impairs Clearance of Phenytoin but Not of Alprazolam or Lorazepam , 1988, Journal of clinical pharmacology.
[224] H K Kroemer,et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. , 1999, The Journal of clinical investigation.
[225] S. Schenker,et al. Lack of effect of nizatidine on hepatic drug metabolism in man. , 1985, British journal of clinical pharmacology.
[226] R. Gugler,et al. Single‐ and multiple‐dose metronidazole kinetics , 1983, Clinical pharmacology and therapeutics.
[227] M. Graham,et al. Pharmacokinetics and Pharmacodynamics of Intravenous Levofloxacin at 750 Milligrams and Various Doses of Metronidazole in Healthy Adult Subjects , 2004, Antimicrobial Agents and Chemotherapy.
[228] R. Herman,et al. Multiple-dose lorazepam kinetics: shuttling of lorazepam glucuronide between the circulation and the gut during day- and night-time dosing intervals in response to feeding. , 1993, The Journal of pharmacology and experimental therapeutics.
[229] F. Andreasen,et al. Pharmacokinetics and pharmacodynamics of thiopentone , 1982, Anaesthesia.
[230] M. Rogge,et al. Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses , 1992, Antimicrobial Agents and Chemotherapy.
[231] A. Hoeft,et al. The Performance of a Target-Controlled Infusion of Propofol in Combination with Remifentanil: A Clinical Investigation with Two Propofol Formulations , 2006, Anesthesia and analgesia.
[232] D. Greenblatt,et al. Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation. , 1985, The Journal of pharmacology and experimental therapeutics.
[233] J. Secor,et al. The Effect of Route of Administration on the Cimetidine‐Theophylline Drug Interaction , 1989, Journal of clinical pharmacology.
[234] Meindert Danhof,et al. Pharmacokinetic‐pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite α‐hydroxymidazolam in healthy volunteers , 1992, Clinical pharmacology and therapeutics.
[235] F. Kunimoto,et al. Plasma concentration for optimal sedation and total body clearance of propofol in patients after esophagectomy , 2004, Journal of Anesthesia.
[236] P. Duvaldestin,et al. Thiopentone pharmacokinetics in patients with chronic alcoholism. , 1984, British journal of anaesthesia.
[237] Pharmacokinetics of Cisatracurium in Patients Receiving Nitrous Oxide/Opioid/Barbiturate Anesthesia , 1996 .
[238] A. Fine,et al. Furosemide kinetics in renal failure , 1978, Clinical pharmacology and therapy.
[239] Ravi K. Deshpande,et al. Acceleration of digoxin clearance by activated charcoal , 1985, Clinical pharmacology and therapeutics.
[240] M. Danhof,et al. Pharmacokinetics, induction of anaesthesia and safety characteristics of propofol 6% SAZN vs propofol 1% SAZN and Diprivan-10 after bolus injection. , 1999, British journal of clinical pharmacology.
[241] G. Drusano,et al. Multiple‐dose ciprofloxacin dose ranging and kinetics , 1985, Clinical pharmacology and therapeutics.
[242] E. Olofsen,et al. Propofol Alters the Pharmacokinetics of Alfentanil in Healthy Male Volunteers , 2001, Anesthesiology.
[243] I. Jang,et al. Pharmacokinetic and Pharmacodynamic Interaction of Lorazepam and Valproic Acid in Relation to UGT2B7 Genetic Polymorphism in Healthy Subjects , 2008, Clinical pharmacology and therapeutics.
[244] J. Scribante,et al. Pharmacokinetic Profiles of High-Dose Intravenous Ciprofloxacin in Severe Sepsis , 1998, Antimicrobial Agents and Chemotherapy.
[245] P. G. Burch,et al. The Role of Metabolism and Protein Binding in Thiopental Anesthesia , 1983, Anesthesiology.
[246] P. Carrupt,et al. Pharmacokinetics of beta-adrenoceptor blockers in obese and normal volunteers. , 1997, British journal of clinical pharmacology.
[247] J. Collier,et al. Comparison of the pharmacokinetics of metronidazole in healthy female volunteers following either a single oral or intravenous dose. , 1979, British journal of clinical pharmacology.
[248] S. Schenker,et al. Effects of aging and liver disease on disposition of lorazepam , 1978, Clinical pharmacology and therapeutics.